Skip to main content

Table 1 Patient demographics and disease characteristics

From: HE4 as a serum biomarker for the diagnosis of pelvic masses: a prospective, multicenter study in 965 patients

 

All (N = 965)

Benign tumors (N = 804)

Ovarian cancer and borderline tumors (N = 161)

Median age at diagnosis, years (range)

48 (18–86) (n = 853a)

45 (18–86) (n = 704a)

59 (27–84) (n = 149a)

Menopausal status, n (%)

 Premenopausal

549 (56.9)

501 (62.3)

48 (29.8)

 Postmenopausal

362 (37.5)

251 (31.2)

111 (68.9)

 Unknown

54 (5.6)

52 (6.5)

2 (1.2)

Median biomarker measurements, U/mL (range)

 CA125

18.4 (2–11,616)

16.1 (2–6522)

159.2 (6.1–11,616)

 HE4

54.52 (13.19–5039)

51.61 (13.19–5039)

149.50 (28.28–4676)

FIGO stage, n (%)

 IA

44 (4.6)

44 (27.3)

 IB

3 (0.3)

3 (1.9)

 IC

12 (1.2)

12 (7.5)

 IIA

3 (0.3)

3 (1.9)

 IIB

2 (0.2)

2 (1.2)

 IIC

4 (0.4)

4 (2.5)

 IIIA

4 (0.4)

4 (2.5)

 IIIB

7 (0.7)

7 (4.3)

 IIIC

52 (5.4)

52 (32.3)

 IV

30 (3.1)

30 (18.6)

Benign tumor type, n (%)

 Cystadenoma

179 (18.5)

179 (22.3)

 Functional cyst

165 (17.1)

165 (20.5)

 Endometriosis

109 (11.3)

109 (13.6)

 Cystadenofibroma

47 (4.9)

47 (5.8)

 Dermoid cyst

44 (4.6)

44 (5.5)

 Inclusion cyst

44 (4.6)

44 (5.5)

 Teratoma

34 (3.5)

34 (4.2)

 Endometrioid tumor

20 (2.1)

20 (2.5)

 Tubo-ovarian abscess

17 (1.8)

17 (2.1)

 Fibroma

15 (1.6)

15 (1.9)

 Benign Brenner tumor

5 (0.5)

5 (0.6)

 Other

124 (12.8)

125 (15.2)

  1. FIGO Fédération Internationale de Gynécologie et d’Obstétrique, HE4 Human epididymis protein 4
  2. aPatients aged < 18 years were not included